Nature Reviews Neurology - Table of Contents alert Volume 13 Issue 2

If you are unable to see the message below, click here to view.

Advertisement
Focus on the neuroscience toolbox Nature Neuroscience presents a special focus issue on the neuroscience toolbox highlighting recent technological advances, approaches and collaborative initiatives that are enabling new avenues of research.  Access the Focus free online for six months Produced with support from:  The Kavli Foundation
TABLE OF CONTENTS
February 2017 Volume 13 Number 2		Advertisement
2015 2-year Impact Factor 18.418 Journal Metrics 2-year Median 13	In this issue Research Highlights Year in Review Reviews Perspectives Also this month  Featured article: The psychosis spectrum in Parkinson disease Dominic H. ffytche, Byron Creese, Marios Politis, K. Ray Chaudhuri, Daniel Weintraub, Clive Ballard & Dag Aarsland	Animation: Alzheimer's disease Nature Neuroscience presents this animation, which introduces the molecular, cellular and physiological mechanisms associated with Alzheimer's disease and highlights some of the most recent advances in our understanding of the onset and progression of this devastating neurological condition. Watch the Animation free online >>
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease. Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation. Open for submissions >>
RESEARCH HIGHLIGHTS Top Alzheimer disease: Soluble TREM2 in CSF sheds light on microglial activation in AD Published online: 13 January 2017 p65 | doi:10.1038/nrneurol.2016.203 PDF Parkinson disease: Could gut microbiota influence severity of Parkinson disease? Published online: 16 December 2016 p66 | doi:10.1038/nrneurol.2016.195 PDF Neuroimmunology: Could antibodies cause psychosis? Published online: 23 December 2016 p66 | doi:10.1038/nrneurol.2016.198 PDF Motor neuron disease: Nusinersen potentially effective in SMA Published online: 23 December 2016 p66 | doi:10.1038/nrneurol.2016.199 PDF IN BRIEF Migraine: Migraine is associated with increased risk of perioperative ischaemic stroke | Stroke: Thrombolytic removal of intraventricular haemorrhage does not improve outcomes | Motor neuron disease: Sparing of oligodendrocytes in a mouse model of spinal muscular atrophy | Peripheral neuropathies: Atypical Charcot-Marie-Tooth disease linked to sphingosine 1-phosphate lyase deficiency PDF Neurology JOBS of the week Research Fellow - Neurology Mayo Clinic Psychiatry - Research Faculty Position The University of Alabama More Science jobs from Neurology EVENT 15th European Neurology Congress 29.08.17 London, UK More science events from
YEAR IN REVIEW		Top
CNS Infections in 2016: 2016, the year of Zika virus Diederik van de Beek & Matthijs C. Brouwer Published online: 13 January 2017 p69 | doi:10.1038/nrneurol.2016.202 In 2016, the literature on neurological infections was, understandably, dominated by Zika virus. However, we should not overlook important publications on the treatment of cryptococcal and bacterial meningitis. Full Text | PDF
Neuro-oncology in 2016: Advances in brain tumour classification and therapy Matthias Preusser & Christine Marosi Published online: 20 January 2017 p71 | doi:10.1038/nrneurol.2017.3 Brain tumours encompass a heterogeneous collection of neoplasms, traditionally classified by histopathological criteria. In 2016, the WHO published an updated classification that, for the first time, defines brain tumour types according to integrated histological and molecular parameters. Furthermore, clinical trial results were reported that inform therapeutic decision-making in diffuse gliomas. Full Text | PDF
Multiple sclerosis in 2016: Immune-directed therapies in MS — efficacy and limitations Bernhard Hemmer & Mark Mühlau Published online: 20 January 2017 p72 | doi:10.1038/nrneurol.2017.2 In 2016, new highly active treatment options for relapsing-remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS. Full Text | PDF
Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test Eric M. Reiman Published online: 13 January 2017 p74 | doi:10.1038/nrneurol.2017.1 Investigational treatments to impede the progression of Alzheimer disease (AD) are being evaluated in clinical trials, and biomarkers to detect and track the disease are being developed and deployed. Recent findings underscore the importance of ongoing clinical trials and biomarker developments in the understanding, treatment and prevention of AD. Full Text | PDF
Movement disorders in 2016: Progress in Parkinson disease and other movement disorders Joseph Jankovic Published online: 13 January 2017 p76 | doi:10.1038/nrneurol.2016.204 In the field of movement disorders, areas that have seen important advances in 2016 include the pathogenesis of Parkinson disease involving extra-CNS α-synuclein pathology, treatment of hyperkinetic disorders with novel dopamine-depleting drugs, and MRI-guided ultrasound surgery for the treatment of essential tremor. Full Text | PDF
Stroke in 2016: Stroke is treatable, but prevention is the key Ale Algra & Marieke J. H. Wermer Published online: 20 January 2017 p78 | doi:10.1038/nrneurol.2017.4 The past 2 years have seen major breakthroughs in endovascular treatment for acute ischaemic stroke. As highlighted in 2016, we now need to refine the logistics for delivery of this treatment, including patient selection. We should not forget, however, that it is better to prevent strokes in the first place. Full Text | PDF
REVIEWS		Top
The psychosis spectrum in Parkinson disease Dominic H. ffytche et al. Published online: 20 January 2017 p81 | doi:10.1038/nrneurol.2016.200 The publication of a consensus definition of Parkinson disease (PD) psychosis in 2007 led to a rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. The authors review this literature and discuss the evolving view of PD psychosis, from distinct classes of symptoms to a continuum progressing over the course of PD. Abstract | Full Text | PDF
Gene discovery in amyotrophic lateral sclerosis: implications for clinical management Ammar Al-Chalabi, Leonard H. van den Berg & Jan Veldink Published online: 16 December 2016 p96 | doi:10.1038/nrneurol.2016.182 Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize genes that are associated with ALS, and describe what is currently known about the genetic architecture of ALS. Abstract | Full Text | PDF | Supplementary information
Treatment decisions in multiple sclerosis — insights from real-world observational studies Maria Trojano et al. Published online: 13 January 2017 p105 | doi:10.1038/nrneurol.2016.188 Real-world observational studies have the potential to answer questions about multiple sclerosis (MS) treatment that randomized controlled trials cannot. Trojano and colleagues discuss the pitfalls and necessary safeguards in observational studies, and the insights that such studies have provided into treatment decisions for patients with MS. Abstract | Full Text | PDF
PERSPECTIVES		Top
SCIENCE AND SOCIETY Precision medicine for disease modification in Parkinson disease Alberto J. Espay, Patrik Brundin & Anthony E. Lang Published online: 20 January 2017 p119 | doi:10.1038/nrneurol.2016.196 In this Perspectives article, Espay and colleagues argue that that the adoption of precision medicine in Parkinson disease will require a revision of biomarker development efforts, with the ultimate goal of testing putative disease-modifying interventions in well-defined disease subgroups. Full Text | PDF
Erratum: Unruptured intracranial aneurysms: development, rupture and preventive management Nima Etminan & Gabriel J. Rinkel Published online: 01 February 2017 p126 | doi:10.1038/nrneurol.2017.14 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.